Abstract: An approach to implementing or configuring an Oblivious RAM (ORAM), which in addition to behaving as a RAM, provides a way to meet a specified degree of privacy in a manner that avoids applying unnecessary computation resources (computation time and/or storages space and/or data transfer) to achieve the specified degree of privacy. In this way, a tradeoff between privacy and computation resources may be tuned to address requirements of a particular application. This ability to tune this tradeoff is not found in other ORAM implementations, which in general aim to achieve complete privacy. In some implementations, the ORAM provides a constant bandwidth overhead compared to conventional RAMs, while achieving a statistical privacy as desired by the user.

Abstract: An approach to implementing or configuring an Oblivious RAM (ORAM), which in addition to behaving as a RAM, provides a way to meet a specified degree of privacy in a manner that avoids applying unnecessary computation resources (computation time and/or storages space and/or data transfer) to achieve the specified degree of privacy. In this way, a tradeoff between privacy and computation resources may be tuned to address requirements of a particular application. This ability to tune this tradeoff is not found in other ORAM implementations, which in general aim to achieve complete privacy. In some implementations, the ORAM provides a constant bandwidth overhead compared to conventional RAMs, while achieving a statistical privacy as desired by the user.

Abstract: The invention relates to adjunctive and simultaneous combination therapies for the treatment of psychotic disorders in which sabcomeline or a pharmaceutically acceptable salt thereof and at least one other neuroleptic agent are administered adjunctively or simultaneously. The invention provides methods of treatment of psychotic disorders utilising such adjunctive or simultaneous therapeutic combination therapies, therapeutic combinations for use therein and pharmaceutical compositions comprising them.

Abstract: The invention relates to the use of sabcomeline or a pharmaceutically acceptable salt thereof in monotherapy for the treatment of bipolar disorder or mania or and to adjunctive and simultaneous combination therapies for the treatment of bipolar disorder or mania in which sabcomeline or a pharmaceutically acceptable salt thereof and at least one other mood stabilizing or antimanic agent are administered adjunctively or simultaneously. The invention provides methods of treatment of bipolar disorder or mania utilizing such monotherapy and such adjunctive or simultaneous therapeutic combination therapies, therapeutic combinations for use therein and pharmaceutical compositions comprising them.